Catalog No.
RHD57904
Species reactivity
Human, Rat
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
IP: 1:20, WB: 1:500-1:1000
Target
JAK1B, JAK1, Janus kinase 1, Tyrosine-protein kinase JAK1, JAK1A, JAK-1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P23458
Applications
IP, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.5% BSA, 0.05% Sodium Azide and 50% Glycerol.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3G35
IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia., PMID:40526840
Mouse Th2 cell extracellular vesicles promote eosinophil survival through the surface cytokine cargo IL-3., PMID:40505836
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates., PMID:40502981
Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab., PMID:40317605
Emerging Therapeutic Approaches for Anemia in Myelofibrosis., PMID:40317385
Bone marrow mesenchymal stem cells alleviate liver fibrosis after rat liver transplantation through JAK1/STAT5 pathway., PMID:40312752
Enhanced Immunity and Infection Resistance in Mice Through Co-Expression of Porcine IL-3, IL-7, and IL-15 Fusion Molecules in Yarrowia lipolytica., PMID:40282231
Modulating IL-21-driven B cell responses in idiopathic inflammatory myopathies via inhibition of the JAK/STAT pathway., PMID:40170058
Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice., PMID:40165566
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials., PMID:39969783
The systemic lupus erythematosus-associated NCF190H allele synergizes with viral infection to cause mouse lupus but also limits virus spread., PMID:39939342
Innovative Therapies and Strategies for Rheumatoid Arthritis., PMID:39871551
A biodegradable magnesium alloy promotes subperiosteal osteogenesis via interleukin-10-dependent macrophage immunomodulation., PMID:39862617
The JAK1/3 Inhibitor Tofacitinib Regulates Th Cell Profiles and Humoral Immune Responses in Myasthenia Gravis., PMID:39821232
Monoallelic expression can govern penetrance of inborn errors of immunity., PMID:39743591
Type 2 cytokine-JAK1 signaling is involved in the development of dry skin-induced mechanical alloknesis., PMID:39616021
Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC., PMID:39493309
Use of Upadacitinib to Treat a Severe Flare-Up of Rheumatoid Arthritis During Anti-PD-1 Immune Checkpoint Inhibitor Therapy for Stage IV Squamous Cell Carcinoma of the Lung., PMID:39458207
Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR., PMID:39415210
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing., PMID:39381601
A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System., PMID:39362623
Th2 cell extracellular vesicles promote eosinophil survival through the cytokine cargo IL-3 and prolong airway eosinophilia., PMID:39211207
The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells., PMID:39188724
Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development., PMID:39164066
From pre-clinical efficacy to promising clinical trials that delay Type 1 diabetes., PMID:39142538
Systemic Lupus Erythematosus and Cytokine Storm., PMID:39117826
The binding of extracellular cyclophilin A to ACE2 and CD147 triggers psoriasis-like inflammation., PMID:39096717
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)., PMID:38967662
Vitamin D3 attenuates autoimmune thyroiditis by regulating Th17/Treg cell differentiation via YAP/JAK1/STAT1 axis., PMID:38959983
APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1., PMID:38909500
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment., PMID:38885318
A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia., PMID:38806478
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study., PMID:38776484
The clonal hematopoiesis mutation Jak2V617F aggravates endothelial injury and thrombosis in arteries with erosion-like intimas., PMID:38759798
Helicobacter pylori disrupts gastric mucosal homeostasis by stimulating macrophages to secrete CCL3., PMID:38730482
Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization., PMID:38701735
Combined Use of Emapalumab With Ruxolitinib and Dexamethasone as an Effective Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis Complicated With Multiorgan Damage and Severe Infection., PMID:38691058
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting., PMID:38649997
Autoantigenic Peptide and Immunomodulator Codelivery System for Rheumatoid Arthritis Treatment by Reestablishing Immune Tolerance., PMID:38598749
A case of dupilumab-induced psoriasis-like eruption treated with baricitinib., PMID:38577056
Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque., PMID:38562119
Effectiveness of tofacitinib monotherapy for patients with IgG4-RD or idiopathic retroperitoneal fibrosis., PMID:38530663
Learning from nemolizumab: A promising therapy for prurigo nodularis., PMID:38460679
Interleukin-4 from curcumin-activated OECs emerges as a central modulator for increasing M2 polarization of microglia/macrophage in OEC anti-inflammatory activity for functional repair of spinal cord injury., PMID:38448976
Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice., PMID:38439732
Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer., PMID:38379418
Case report: Refractory Evans syndrome in two patients with spondyloenchondrodysplasia with immune dysregulation treated successfully with JAK1/JAK2 inhibition., PMID:38347954
Prurigo nodularis: new insights into pathogenesis and novel therapeutics., PMID:38345154
Radical S-adenosyl methionine domain-containing 2, a potential target of D-tryptophan in asthma treatment, regulates T helper cell type 1/2 balance., PMID:38310765
Novel Management of Masticatory Myositis in Three Dogs with a Selective Janus Kinase (JAK-1) Inhibitor., PMID:38192103
For research use only. Not for human or drug use.
